Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Common Equity: 2012-2024

Historic Common Equity for Ocular Therapeutix (OCUL) over the last 13 years, with Dec 2024 value amounting to $315.3 million.

  • Ocular Therapeutix's Common Equity fell 26.64% to $258.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $258.2 million, marking a year-over-year decrease of 26.64%. This contributed to the annual value of $315.3 million for FY2024, which is 246.03% up from last year.
  • Per Ocular Therapeutix's latest filing, its Common Equity stood at $315.3 million for FY2024, which was up 246.03% from $91.1 million recorded in FY2023.
  • Over the past 5 years, Ocular Therapeutix's Common Equity peaked at $315.3 million during FY2024, and registered a low of $35.4 million during FY2022.
  • Over the past 3 years, Ocular Therapeutix's median Common Equity value was $91.1 million (recorded in 2023), while the average stood at $147.3 million.
  • Per our database at Business Quant, Ocular Therapeutix's Common Equity surged by 2,196.28% in 2020 and then slumped by 59.80% in 2022.
  • Yearly analysis of 5 years shows Ocular Therapeutix's Common Equity stood at $76.1 million in 2020, then grew by 15.64% to $88.0 million in 2021, then tumbled by 59.80% to $35.4 million in 2022, then surged by 157.59% to $91.1 million in 2023, then skyrocketed by 246.03% to $315.3 million in 2024.